Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis
I. Pavord, A. De Soyza, J. S. Elborn, D. Smith, H. Wray, M. Puu, B. Larsson, R. Stockley (Leicester, Newcastle upon Tyne, Belfast, Bristol, Birmingham, United Kingdom; Mölndal, Sweden)
Source: Annual Congress 2013 –New drugs in respiratory medicine
Session: New drugs in respiratory medicine
Session type: Poster Discussion
Number: 1593
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Pavord, A. De Soyza, J. S. Elborn, D. Smith, H. Wray, M. Puu, B. Larsson, R. Stockley (Leicester, Newcastle upon Tyne, Belfast, Bristol, Birmingham, United Kingdom; Mölndal, Sweden). Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis. Eur Respir J 2013; 42: Suppl. 57, 1593
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013
AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014
Efficacy and safety of abediterol, a long-acting beta2 -adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Pharmacological treatment of asthma today Source: Eur Respir J 2001; 18: 34S-40S Year: 2001
The inverse agonist propranolol does not confer steroid-sparing activity in persistent asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Safety, tolerability and pharmacokinetics of CHF 6001, a novel selective inhaled PDE4 inhibitor, in healthy volunteers Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Decoy chemokine neutraligands with anti-asthmatic activity Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
The safety, PK and PD profile of ADC3680, a potent and selective CRTh2 antagonist, in healthy volunteers and partly controlled atopic asthmatic subjects Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016
Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist Source: International Congress 2016 – Asthma management Year: 2016
Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Side effects of the leukotriene receptor antagonists in asthmatic children Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014